The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo
Open accessAbstract
Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor in clinical trials as a cancer therapy that has been recently shown to block human immunodeficiency virus Tat transactivation and viral replication through inhibition of positive transcription elongation factor b (P-TEFb). Flavopiridol is the most potent P-TEFb inhibitor reported and the first Cdk inhibitor that is not competitive with ATP. We examined the ability of flavopiridol to inhibit P-TEFb (Cdk9/cyclin T1) phosphorylation of both RNA polymerase II and the large subunit of the 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) sensitivity-inducing factor and found that the IC(50) determined was directly related to the concentration of the enzyme. We concluded that the flavonoid associates with P-TEFb with 1:1 stoichiometry even at concentrations of enzyme in the low nanomolar range. These results indicate that the apparent lack of competition with ATP could be caused by a very tight binding of the drug. We developed a novel immobilized P-TEFb assay and demonstrated that the drug remains bound for minutes even in the presence of high salt. Flavopiridol remained bound in the presence of a 1000-fold excess of the commonly used inhibitor DRB, suggesting that the immobilized P-TEFb could be used in a simple screening assay that would allow the discovery or characterization of compounds with binding properties similar to flavopiridol. Finally, we compared the ability of flavopiridol and DRB to inhibit transcription in vivo using nuclear run-on assays and concluded that P-TEFb is required for transcription of most RNA polymerase II molecules in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wei, P., Garber, M. E., Fang, S.-M., Fischer, W. H., & Jones, K. A. (1998) · Cell · doi:10.1016/s0092-8674(00)80939-3 · Cited by 1,249
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro
Zhu, Y., Pe’ery, T., Peng, J., Ramanathan, Y., Marshall, N., Marshall, T., Amendt, B., Mathews, M. B., & Price, D. H. (1997) · Genes & Development · doi:10.1101/gad.11.20.2622 · Cited by 696
Self-citationP-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II
Price, D. H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2629-2634.2000 · Cited by 679
Self-citationCarlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 580
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro
Mancebo, H. S. Y., Lee, G., Flygare, J., Tomassini, J., Luu, P., Zhu, Y., Peng, J., Blau, C., Hazuda, D., Price, D., et al. (1997) · Genes & Development · doi:10.1101/gad.11.20.2633 · Cited by 544
Self-citationIdentification of multiple cyclin subunits of human P-TEFb
Peng, J., Zhu, Y., Milton, J. T., & Price, D. H. (1998) · Genes & Development · doi:10.1101/gad.12.5.755 · Cited by 519
Self-citationDe Azevedo, W. F., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., & Kim, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2735 · Cited by 496
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 455
Self-citationGarber, M. E., Wei, P., KewalRamani, V. N., Mayall, T. P., Herrmann, C. H., Rice, A. P., Littman, D. R., & Jones, K. A. (1998) · Genes & Development · doi:10.1101/gad.12.22.3512 · Cited by 431
Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2986 · Cited by 403
Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275
Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., & Worland, P. J. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1742 · Cited by 345
HIV-1 Tat protein promotes formation of more-processive elongation complexes.
Marciniak, R. A., & Sharp, P. A. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04997.x · Cited by 287
Carlson, B., Lahusen, T. J., Singh, S., Loaiza‐Perez, A., Worland, P. J., Pestell, R. G., Albanese, C., Sausville, E. A., & Senderowicz, A. M. (1999) · PubMed · Cited by 287
ATP-site Directed Inhibitors of Cyclin-dependent Kinases
G ray, N., Detivaud, L., Doerig, C., & Meijer, L. (1999) · Current Medicinal Chemistry · doi:10.2174/092986730609220401152358 · Cited by 266
Ribosomal RNA synthesis in isolated nuclei
Reeder, R. H., & Roeder, R. G. (1972) · Journal of Molecular Biology · doi:10.1016/0022-2836(72)90461-5 · Cited by 245
Cyclin K Functions as a CDK9 Regulatory Subunit and Participates in RNA Polymerase II Transcription
Fu, T.-J., Peng, J., Lee, G., Price, D. H., & Flores, O. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34527 · Cited by 223
Self-citationKim, J. B., & Sharp, P. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010908200 · Cited by 208
Ping, Y.-H., & Rana, T. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006130200 · Cited by 206
The Structure-Based Design of ATP-Site Directed Protein Kinase Inhibitors
Toledo, Lydon, N. B., & Elbaum, D. (1999) · Current Medicinal Chemistry · doi:10.2174/092986730609220401150028 · Cited by 176
Fujinaga, K., Cujec, T. P., Peng, J., Garriga, J., Price, D. H., Graña, X., & Peterlin, B. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.9.7154-7159.1998 · Cited by 164
Self-citationTat Transactivation: A Model for the Regulation of Eukaryotic Transcriptional Elongation
Taube, R., Fujinaga, K., Wimmer, J., Barborič, M., & Peterlin, B. M. (1999) · Virology · doi:10.1006/viro.1999.9944 · Cited by 159
Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status
Kèlland, L. R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.12.2903 · Cited by 140
Gold, M. O., Yang, X., Herrmann, C. H., & Rice, A. P. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4448-4453.1998 · Cited by 117
Kim, K. S., Sack, J. S., Tokarski, J. S., Qian, L., Chao, S. T., Leith, L. W., Kelly, Y. F., Misra, R. N., Hunt, J. T., Kimball, S. D., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000231g · Cited by 104
Self-citationFlores, O. A., Lee, G., KESSLER, J. A., Miller, M., Schlief, W., Tomassini, J. E., & Hazuda, D. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7208 · Cited by 71
CDK9 (PITALRE): A multifunctional cdc2-related kinase
Falco, G. D., & Giordano, A. (1998) · Journal of Cellular Physiology · Cited by 64
Structure–activity relationship studies of flavopiridol analogues
Murthi, K. K., Dubay, M., McClure, C., Brizuela, L., Boisclair, M. D., Worland, P. J., Mansuri, M. M., & Pal, K. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00156-6 · Cited by 53
Highly Divergent Lentiviral Tat Proteins Activate Viral Gene Expression by a Common Mechanism
Bieniasz, P. D., Grdina, T. A., Bogerd, H. P., & Cullen, B. R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.4592 · Cited by 38
Egyh�zi, E., Ossoinak, A., Pigon, A., Holmgren, C., Lee, J. M., & Greenleaf, A. L. (1996) · Chromosoma · doi:10.1007/bf00352266 · Cited by 28
Cited by
Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H.-S., Brady, J. N., & Ozato, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.027 · Cited by 1,291
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Controlling the elongation phase of transcription with P-TEFb
Peterlin, B. M., & Price, D. H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.014 · Cited by 1,144
Self-citationRecruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,138
Metadata
- Authors
- Chao, S.-H., & Price, D. H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-08
- Volume
- 276
- Issue
- 34
- Pages
- 31793-31799
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2081567150
- Cited by
- 621
- References
- 31
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.